In short
There is currently 1 ongoing clinical trial investigating treatments for Burning Mouth Syndrome, a condition characterized by a persistent burning sensation in the mouth without an obvious cause. This trial is exploring the use of topical Clonazepam, a medication typically used for seizures and panic disorders, to help manage the burning pain and other symptoms experienced by patients.
Clinical trial locations
Study on Clonazepam for Treating Burning Mouth Syndrome in Patients
This clinical trial is investigating topical Clonazepam as a treatment for Burning Mouth Syndrome. The study is being conducted in Sweden and focuses on understanding how this medication, when applied directly to the affected area in the mouth rather than taken as a pill, can help manage the symptoms of this challenging condition.
Inclusion criteria: To participate in this trial, you must have a confirmed diagnosis of Burning Mouth Syndrome according to the International Classification of Orofacial Pain. Participants must be between 18 and 64 years old. Both men and women are eligible to join the study. The trial is open to individuals who do not belong to vulnerable populations requiring special protection.
Exclusion criteria: The trial excludes individuals outside the specified age range, those without a confirmed diagnosis, and people who belong to vulnerable populations such as those with certain disabilities that would require additional protective measures.
Trial focus and goals: The study is designed in two parts. The first phase lasts two weeks, during which participants will use topical Clonazepam treatment. Researchers will carefully monitor how the treatment affects pain levels, any changes in sensation such as taste, and jaw function. They will also gather feedback about participants' experiences with the treatment. Pain intensity will be measured using a scale from 0 to 10, including current pain, worst pain, and average pain over the previous two weeks. The second phase involves a long-term follow-up over six months, where participants will continue with either Clonazepam or a control treatment without knowing which one they are receiving. This helps researchers understand the long-term effectiveness of the treatment. Throughout the study, various aspects will be monitored, including stress levels, pain-related disability, and overall impression of change in the condition.
Investigational drug: Clonazepam is the medication being studied in this trial. It belongs to a class of medications called benzodiazepines, which are known for their calming effects on the nervous system. In this study, Clonazepam works by enhancing the activity of certain neurotransmitters in the brain, which helps to reduce nerve-related pain. While it is traditionally used to treat seizures and panic disorders when taken as a pill, this trial is exploring its effectiveness when applied topically to the mouth to relieve the burning sensation and associated symptoms.
Summary
Currently, there is one active clinical trial for Burning Mouth Syndrome, taking place in Sweden. This trial represents an important step in exploring alternative treatment approaches for this condition, which can significantly impact daily life and for which effective treatments are still being sought. The focus on topical application of Clonazepam is particularly noteworthy, as it offers a different approach from traditional oral medications and may provide relief with potentially fewer systemic side effects. The two-phase design of the study, including both short-term assessment and long-term follow-up, will provide valuable information about both immediate effectiveness and sustained benefits of this treatment approach.
